Clinical features in adult patients with in-hospital cardiovascular events with confirmed 2009 Influenza A (H1N1) virus infection: Comparison with those without in-hospital cardiovascular events

BackgroundComprehensive data regarding in-hospital cardiovascular events of adults with confirmed 2009 influenza A (H1N1) (2009 H1N1) infections are limited. The aim of this study was to determine the clinical characteristics, laboratory parameters, and electrocardiographic (ECG) findings for adults with 2009 H1N1 infections and to assess the differences in these parameters among adult patients with and without in-hospital cardiovascular events.MethodsSeventy-one patients were enrolled from the 2009 H1N1 registry database (our hospital registry of confirmed 2009 H1N1 infection during the year 2009) and divided according to the presence of in-hospital cardiovascular events. Six patients had cardiovascular events (CV group) and 65 did not (NCV group).ResultsThe CV group was more likely to be old (p = 0.023). Regarding co-morbidities, underlying coronary heart disease (p = 0.001), congestive heart failure (p = 0.001), diabetes (p = 0.001), and hypertension (p = 0.014) had significant influences on cardiovascular events. The CV group was also more likely to have chest pain (p = 0.034), dyspnea (p = 0.045), higher leukocyte count (p = 0.014), higher C-reactive protein (p = 0.010), higher glucose level (p = 0.001), and higher N-terminal probrain natriuretic peptide level (p = 0.010) than the NCV group. In addition, the CV group had a significantly higher in-hospital mortality rate (p = 0.010) and cardiac mortality rate (p = 0.001) than the NCV group. However, there were no significant differences in ECG findings between the two groups.ConclusionOur study demonstrated that the CV group had higher in-hospital and cardiac mortality rates than the NCV group. A meticulous therapeutic approach should be considered for elderly patients with 2009 H1N1 infections having coronary heart disease, congestive heart failure, diabetes, hypertension, and high levels of leukocyte count, hs-CRP, glucose, and NT-proBNP at the time of admission.     

Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness: A Multicenter,Randomized, Controlled,Open‐Label,Parallel‐Group,Clinical Trial

IntroductionAtrophic vaginitis is a common occurrence, particularly among postmenopausal women; however, few seek or receive treatment. One therapeutic solution is topically applied products. Estrogen‐based treatments have been shown to be effective; however, many patients are reluctant to use such formulations due to health concerns, hence the need to assess the efficacy of acceptable alternatives.AimThis multicenter, randomized, controlled, open‐label, parallel‐group clinical trial set out to evaluate the efficacy and safety of hyaluronic acid vaginal gel to treat vaginal dryness compared with estriol cream in postmenopausal women.MethodsOne hundred forty‐four subjects were randomized, 72 to the test group treated with hyaluronic acid vaginal gel (Hyalofemme) and 72 to the control group treated with estriol cream (Ovestin). Treatment in both groups was applied by means of a device once every 3 days for a total of 10 applications over 30 days.Main Outcome MeasuresEfficacy was measured by grading vaginal dryness and three other vaginal symptoms on a visual analog scale. Safety assessments included vital signs, laboratory examinations of the vaginal microecosystem, vaginal pH value, vaginal B ultrasound, and incidence of adverse events. Assessments were performed at baseline, by telephone after the third application, and at the final visit.ResultsBoth hyaluronic acid vaginal gel and estriol cream can significantly improve the clinical symptoms of vaginal dryness in postmenopausal women, with improvement rate of 84.44% and 89.42%, respectively, after 10 applications, without statistically significant difference between them.ConclusionBoth hyaluronic acid vaginal gel and estriol cream are effective in the treatment of vaginal dryness. Hyaluronic acid vaginal gel may be considered as a valid alternative to estrogen‐based treatments in relieving the symptoms of vaginal dryness.     

Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group

Nicotinamide phosphoribosyltransferase (Nampt) was served as a useful biomarker for tumorigenesis and for the prediction of cancer survival. In the present study, we analyzed the SNPs of the NAMPT gene and their impact on the susceptibility and prognosis for patients with bladder cancer (BC). The rs61330082, rs2505568 and rs9034 were selected and genotyped by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) method in 407 patients with bladder cancer and 316 ethnicity-matched healthy control subjects. The genotyping method was confirmed by the DNA sequencing analysis. Statistically significant increased bladder cancer risk was found to be associated with the C allele and CC genotype of rs61330082; nevertheless, decreased bladder cancer risk was revealed to be associated with A allele and AT genotype of rs2505568. Stratified analyses revealed the rs61330082 to be statistically associated with increased bladder cancer risk in smokers and increased invasiveness of bladder cancer. The AT heterozygote of rs2505568 may prevent the recurrence of bladder cancer. Kaplan-Meier curves revealed a statistically significant association of rs2505568 with recurrence-free survival for total bladder cancer patients and non-muscle-invasive bladder cancer patients, and a statistically significant association of rs9034 with recurrence-free survival for muscle-invasive bladder cancer patients. Multiple Cox regression analysis identified the rs2505568 as a possible independent prognostic factor for recurrence-free survival in total bladder cancer patients. Our results suggested an important role for NAMPT in the pathogenesis of bladder cancer and SNPs of NAMPT gene might be a novel genetic biomarker for the prognosis of bladder cancer.     

PBMC中CD69、CD107a表达上调在诊断迟发型药物变态反应中的意义

目的检测药疹患者外周血单个核细胞中CD69和CD107a的表达,评价其与迟发型药物变态反应的相关性。方法 2010年5月至2011年4月采集20例药疹患者和10例健康对照者的外周血,用淋巴细胞分离液分离外周血单个核细胞,按2×106细胞/孔种植于24孔板,给予致敏药物刺激,培养72 h后采用流式细胞术染色并检测外周血单个核细胞中CD69和CD107a分子的表达。结果健康对照组外周血单个核细胞中CD107a阳性、CD69阳性、CD107a与CD69双阳性细胞刺激前的比例分别为(0.41±0.18)%、(0.33±0.13)%、(0.12±0.06)%,经致敏药物刺激后分别为(0.38±0.28)%、(0.35±0.12)%、(0.14±0.08)%,刺激前后无明显差异,药疹患者外周血单个核细胞中CD107a阳性、CD69阳性、CD107a与CD69双阳性细胞刺激前的比例分别为(0.45±0.25)%、(0.31±0.12)%、(0.15±0.07)%,与健康对照组无明显差异,但经致敏药物刺激后外周血单个核细胞中CD69阳性、CD107a阳性、CD107a与CD69双阳性细胞表达比例明显增高[分别为(9.01±2.91)%、(1.78±0.76)%、(0.74±0.19)%],和健康对照组、药疹未刺激组比较有统计学差异(P<0.01),且随着致敏药物浓度的增加,CD69和CD107a的表达呈剂量依赖性上调。结论药疹患者外周血单个核细胞经致敏药物刺激后CD69、CD107a表达增加。     

WWOX基因对人急性淋巴细胞性白血病细胞CCRF-CEM细胞凋亡及细胞周期的影响

目的:研究WWOX基因对人急性淋巴细胞性白血病细胞CCRF-CEM细胞凋亡及细胞周期的影响及分子机制。方法:体外培养CCRF-CRM细胞系，将WWOX基因转染入CCRF-CEM细胞，建立高表达WWOX的CCRF-CEM细胞，流式细胞仪法测定CCRF-CEM细胞的细胞周期和凋亡，Western blot法测定WWOX基因、细胞周期和凋亡相关因子的蛋白表达，qRT-PCR法测定caspase-3的mRNA表达。结果:与对照组和空白质粒组相比，转染入WWOX的CCRF-CEM细胞的WWOX蛋白表达显著增加，G0/G1期的细胞比例显著增加，凋亡细胞比例显著增加；CCRF-CEM细胞中cyclin D1、cyclin E、CDK2的蛋白表达显著降低而Wnt-5α和JNK的蛋白表达显著增加，caspase-3的mRNA表达促进CCRF-CEM细胞的凋亡。结论:WWOX基因在急性淋巴细胞性白血病CCRF-CEM细胞中发挥抑癌基因作用，可以有效促进细胞凋亡并抑制细胞周期进程。     

Matteucens I-J,phenolics from the rhizomes of Matteuccia orientalis

Two new phenolics, named matteucens I-J (1-2), were isolated from the 60% EtOH extract of the rhizomes of Matteuccia orientalis (HOOK.) TREV. Their structures were elucidated by means of extensive spectroscopic analysis (HRESIMS, NMR).     

左炔诺孕酮宫内节育系统预防子宫内膜异位症复发的临床疗效

目的探讨左炔诺孕酮宫内节育系统(LNG-IUD)用于卵巢子宫内膜异位症保守性手术后的疗效、安全性以及复发情况。方法选取72例进行卵巢子宫内膜异位症保守性手术的患者作为研究对象,其中36例于术后第1次月经来潮予以放置LNG-IUD,另36例术后应用促性腺激素释放激素激动剂(GnRH-a)、中成药或未采取任何措施,于术后第3、6、12月观察其卵巢大小、卵巢功能、内膜厚度、糖类抗原125(CA125)、人附睾蛋白4(HE4)以及其痛经等情况的变化。结果 LNG-IUD可有效的预防卵巢子宫内膜异位囊肿腹腔镜保守性手术后的术后复发,同时可以缓解痛经、减少月经量、降低CA125水平,且对卵巢功能无影响。结论 LNG-IUD适用于预防卵巢子宫内膜异位症复发且患者依从性好。